Reviewing Antares Pharma (ATRS) and Zimmer Biomet (ZBH)

Antares Pharma (NASDAQ: ATRS) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, dividends and valuation.

Dividends

Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 0.8%. Antares Pharma does not pay a dividend. Zimmer Biomet pays out 30.2% of its earnings in the form of a dividend.

Profitability

This table compares Antares Pharma and Zimmer Biomet’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Antares Pharma -32.06% -43.05% -24.14%
Zimmer Biomet 8.36% 16.29% 6.17%

Insider & Institutional Ownership

34.7% of Antares Pharma shares are held by institutional investors. Comparatively, 86.2% of Zimmer Biomet shares are held by institutional investors. 11.6% of Antares Pharma shares are held by insiders. Comparatively, 1.1% of Zimmer Biomet shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Antares Pharma and Zimmer Biomet, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Antares Pharma 0 0 3 1 3.25
Zimmer Biomet 1 6 14 1 2.68

Antares Pharma presently has a consensus price target of $3.95, suggesting a potential upside of 124.43%. Zimmer Biomet has a consensus price target of $135.40, suggesting a potential upside of 19.41%. Given Antares Pharma’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Antares Pharma is more favorable than Zimmer Biomet.

Risk and Volatility

Antares Pharma has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.

Earnings & Valuation

This table compares Antares Pharma and Zimmer Biomet’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Antares Pharma $52.22 million 5.28 -$24.33 million ($0.11) -16.00
Zimmer Biomet $7.68 billion 2.99 $305.90 million $3.18 35.66

Zimmer Biomet has higher revenue and earnings than Antares Pharma. Antares Pharma is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Summary

Zimmer Biomet beats Antares Pharma on 10 of the 15 factors compared between the two stocks.

About Antares Pharma

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company’s subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc. is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company’s products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. The Company manages its operations through three geographic operating segments: the Americas, consisting principally of the United States and other North, Central and South American markets; EMEA, consisting principally of Europe and the Middle East and African markets, and Asia Pacific, consisting primarily of Japan and other Asian and Pacific markets. The Company’s product category segments include Americas Spine, Office Based Technologies, Craniomaxillofacial and Thoracic (CMF), and Dental.

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply